期刊文献+

传播阻断型恶性疟疾疫苗的研究进展 被引量:1

Advances in research on malignant malaria transmission-blocking vaccine
下载PDF
导出
摘要 迄今为止,恶性疟疾仍然是严重威胁人类健康的传染性疾病之一。由于抗药性疟原虫的出现,研究安全、有效且廉价的恶性疟疾疫苗迫在眉睫。综述了当前在研究中的3种恶性疟疾疫苗,并从候选抗原性质、当前研究中的问题和抗原免疫原性等方面重点介绍了传播阻断型恶性疟疾疫苗的现状,为传播阻断型疟疾疫苗的研发提供了参考。 Malignant malaria is one of the most serious infectious diseases which has ever been threatening people' s life and health until now. It is due to the spread of drug-resistant malaria parasites and mosquito, the urgent need is the study and development of safe, effective and cheap vaccine for malaria. There are three Plasmodium falciparum malaria vaccines at present, including Pre-erythrocyfic stage vaccine, Erythrocytic stage vaccines, and Transmission blocking Vaccines. On the purpose to provide some theoritical consideration on the related research, we focus on the application of transmission- blocking vaccines, target antigens, immunogenicity of candidate antigen and development state in the review.
出处 《微生物学免疫学进展》 2013年第3期84-88,共5页 Progress In Microbiology and Immunology
关键词 恶性疟疾 传播阻断型疫苗 免疫原性 Malaria Transmission blocking vaccine Immunogcnicity
  • 相关文献

参考文献28

  • 1WHO. World Malaria Report 2010[ EB/OL]. http://www, who. int/malaria/publicati-ons/atoz/9789241564106/en/index, html.
  • 2张冬梅,潘卫庆.我国疟疾疫苗研究进展及前景[J].中国寄生虫学与寄生虫病杂志,2009,27(5):390-393. 被引量:12
  • 3Asante KP, Abdulla S, Agnandji S, et al. Safety and efficacy of the RTS, S/AS01 E candidate malaria vaccine given with expanded- programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial [ J ]. Lancet Infect Dis, 2011 , 11 (10) :741-749.
  • 4Sagara I, Dicko A, Ellis RD, et al. A randomized controlled Phase 2 trial of the blood stage AMA1 -C1/Alhydrogel malaria vac- cine in children in Mali [ J]. Vaccine,2009,27:3090-3098.
  • 5Ogutu BR, Apollo OJ, McKinney D, et al. Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations con- fers no protection to young children in Western Kenya[ J]. PLoS One, 2009,4 : e4708.
  • 6Weedall GD, Conway DJ. Detecting signatures of balancing selec- tion to identify targets of anti-parasite immunity [ J]. Trends Para- sitol, 2010, 26:363-369.
  • 7潘卫庆.疟疾疫苗研究的现状和展望[J].第二军医大学学报,2004,25(1):1-4. 被引量:12
  • 8Gwadz RW. Successful immunization against the sexual stages of Plasmodium gallinaceum [ J ]. Science, 1976, 193 (4258) : 1150- 1151.
  • 9Carter R. Malaria transmission-blocking vaccines-how can their development be supported [ J ]. Nature Medicine, 2000, 6 ( 3 ) : 241-244.
  • 10Coutinho-Abreu IV, Ramalho-Ortigao M. Transmission blocking vaccines to control insect-brone disease-A Review[ J]. Mere Inst Oswaldo Cruz Rio de Janeiro, 2010, 105 ( 1 ) : 1-12.

二级参考文献43

  • 1李淑梅,李珣,缪军,刘忠湘,薛采芳.以恶性疟原虫MSP1和AMA1疫苗组合免疫小鼠诱导保护性免疫[J].中国人兽共患病学报,2006,22(10):936-940. 被引量:3
  • 2Moorthy VS, Pinder M, Reece WH, et al. Safety and immunogenicity of DNA/modified vaccinia virus ankara malaria vaccination in African adults[J]. J Infect Dis, 2003, 188(8): 1239-1244.
  • 3Hoffman SL, Goh LM, Luke TC, et al. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites[J]. J Infect Dis, 2002, 185(8): 1155-1164.
  • 4Long CA, Hoffman SL. Enhanced: Malaria-from infants to genomics to vaccines[J]. Science, 2002, 297(5580): 345-347.
  • 5Preiser PR, Khan S, Costa FT, et al. Stage-specific transcription of distinct repertoires of a multigene family during plasmodium life cycle[J]. Science, 2002, 295(5553): 342-345.
  • 6Bejon P, Lusingu J, Olotu A, et al. Efficacy of RTS, S/AS01E vaccine against malaria in children 5 to 17 months of age[J]. N Engl J Med, 200, 359(24): 2521-2532.
  • 7Gregson AL, Oliveira G, Othoro C, et al. Phase Ⅰ trial of an alhydrogel adjuvanted hepatitis B core vires-like particle containing epitopes of Plasmodium falciparum circumsporozoite protein [J]. PLoS ONE, 2008, 3(2): e1556.
  • 8Malkin E, Long CA, Stowers AW, et al. Phase 1 study of two merozoite surface protein 1 (MSP1--42) vaccines for Plasmodium falciparum malaria[J]. PLOS Clin Trial, 2007, 2(4): e12.
  • 9Bojang KA, Milligan PJM, Pinder L, et al. Efficacy of RTS,S/ AS02 malaria vaccine against Plasmodium folciparum infection in semi-immune adult men in The Gambia: a randomised trial[J]. Lancet, 2001, 358(9297): 1927-1934.
  • 10Wu Y, Ellis RD, Shaffer D, et al. Phase 1 trial of. malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51[J]. PLoS ONE, 2008, 3(7): e2636.

共引文献26

同被引文献6

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部